Literature DB >> 12607308

[Discussion for gastric cancer treatment guidelines in Japan].

Tsuneo Sasaki1.   

Abstract

The Japan Gastric Cancer Association issued the first version of Gastric Cancer treatment guidelines in March 2001 and those for patients in December 2001. These guidelines aim to reduce differences in treatment selection by institutions and doctors by to provide standard indication for doctors and patients. This guidelines show treatment indications according to the clinical stages of disease. If doctors are planning to offer treatments different from those in the guidelines, they are expected to explain the reasons for this difference to patients. The advantages and disadvantages of the guidelines had been discussed in developing committee and symposium of Japanese gastric cancer association. In these guidelines for patients, [there is no evidence to prevent gastric cancer by Helicobacter pylori eradication.]. But, many studies have yielded a positive relationship between Helicobacter pylori and gastric cancer. These gastric cancer treatment guidelines are significant in every respect, especially medical care and informed consent. Treatment guidelines should be revised associated with developments in the treatment of gastric cancer.

Entities:  

Mesh:

Year:  2003        PMID: 12607308

Source DB:  PubMed          Journal:  Nihon Rinsho        ISSN: 0047-1852


  2 in total

Review 1.  Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach.

Authors:  Jun Haeng Lee; Jae G Kim; Hye-Kyung Jung; Jung Hoon Kim; Woo Kyoung Jeong; Tae Joo Jeon; Joon Mee Kim; Young Il Kim; Keun Won Ryu; Seong-Ho Kong; Hyoung-Il Kim; Hwoon-Yong Jung; Yong Sik Kim; Dae Young Zang; Jae Yong Cho; Joon Oh Park; Do Hoon Lim; Eun Sun Jung; Hyeong Sik Ahn; Hyun Jung Kim
Journal:  J Gastric Cancer       Date:  2014-06-30       Impact factor: 3.720

2.  lncRNA LIFR‑AS1 inhibits gastric carcinoma cell proliferation, migration and invasion by sponging miR‑4698.

Authors:  Jiangqiao Zhao; Xiaoning Li; Liping Fu; Na Zhang; Jiaping Yang; Jianhui Cai
Journal:  Mol Med Rep       Date:  2020-12-23       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.